Insider Selling: Protagonist Therapeutics Inc (PTGX) Major Shareholder Sells 77,591 Shares of Stock

Protagonist Therapeutics Inc (NASDAQ:PTGX) major shareholder X L.P. Canaan sold 77,591 shares of the stock in a transaction that occurred on Monday, May 14th. The shares were sold at an average price of $6.37, for a total value of $494,254.67. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Large shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

X L.P. Canaan also recently made the following trade(s):

  • On Wednesday, May 16th, X L.P. Canaan sold 164,747 shares of Protagonist Therapeutics stock. The shares were sold at an average price of $6.42, for a total value of $1,057,675.74.
  • On Thursday, March 22nd, X L.P. Canaan sold 39,518 shares of Protagonist Therapeutics stock. The shares were sold at an average price of $20.61, for a total value of $814,465.98.
  • On Monday, March 19th, X L.P. Canaan sold 20,365 shares of Protagonist Therapeutics stock. The shares were sold at an average price of $20.55, for a total value of $418,500.75.
  • On Tuesday, March 13th, X L.P. Canaan sold 1,204 shares of Protagonist Therapeutics stock. The shares were sold at an average price of $20.84, for a total value of $25,091.36.
  • On Thursday, March 15th, X L.P. Canaan sold 13,155 shares of Protagonist Therapeutics stock. The shares were sold at an average price of $20.66, for a total value of $271,782.30.

Shares of NASDAQ PTGX remained flat at $$6.45 during trading hours on Wednesday. The company had a trading volume of 201,700 shares, compared to its average volume of 209,349. The firm has a market capitalization of $136.13 million, a price-to-earnings ratio of -3.09 and a beta of 3.54. Protagonist Therapeutics Inc has a twelve month low of $6.34 and a twelve month high of $6.50.

Protagonist Therapeutics (NASDAQ:PTGX) last issued its earnings results on Wednesday, May 9th. The company reported ($0.36) EPS for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.07). The company had revenue of $10.78 million during the quarter, compared to analyst estimates of $10.70 million. sell-side analysts forecast that Protagonist Therapeutics Inc will post -0.98 EPS for the current fiscal year.

Several equities research analysts have recently weighed in on the company. Stifel Nicolaus cut Protagonist Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, March 26th. BMO Capital Markets reissued an “outperform” rating and issued a $42.00 price objective (down from $44.00) on shares of Protagonist Therapeutics in a research report on Thursday, March 8th. Zacks Investment Research raised Protagonist Therapeutics from a “hold” rating to a “buy” rating and set a $26.00 price objective for the company in a research report on Tuesday, March 13th. Finally, BidaskClub cut Protagonist Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, January 19th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $26.75.

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Wells Fargo & Company MN raised its stake in shares of Protagonist Therapeutics by 60.8% in the third quarter. Wells Fargo & Company MN now owns 9,565 shares of the company’s stock valued at $169,000 after purchasing an additional 3,617 shares in the last quarter. Teachers Advisors LLC raised its stake in shares of Protagonist Therapeutics by 33.1% in the fourth quarter. Teachers Advisors LLC now owns 21,593 shares of the company’s stock valued at $449,000 after purchasing an additional 5,375 shares in the last quarter. Bank of Montreal Can raised its stake in shares of Protagonist Therapeutics by 1,086.0% in the fourth quarter. Bank of Montreal Can now owns 5,930 shares of the company’s stock valued at $123,000 after purchasing an additional 5,430 shares in the last quarter. Schwab Charles Investment Management Inc. raised its stake in shares of Protagonist Therapeutics by 46.2% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 19,300 shares of the company’s stock valued at $402,000 after purchasing an additional 6,100 shares in the last quarter. Finally, Cubist Systematic Strategies LLC raised its stake in shares of Protagonist Therapeutics by 255.0% in the first quarter. Cubist Systematic Strategies LLC now owns 11,593 shares of the company’s stock valued at $100,000 after purchasing an additional 8,327 shares in the last quarter. Institutional investors and hedge funds own 56.00% of the company’s stock.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc is a clinical-stage biopharmaceutical company with a peptide technology platform focused on discovering and developing new chemical entities (NECs) to address significant unmet medical needs. The Company’s product pipeline includes PTG-100, PTG-200 and PTG-300. Its primary focus is on developing oral peptide drugs that target biological pathways also targeted by marketed injectable antibody drugs.

Insider Buying and Selling by Quarter for Protagonist Therapeutics (NASDAQ:PTGX)

Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply